BioCryst to Report Third Quarter 2026 Financial Results on November 4GlobeNewsWire · 3 days ago
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAEGlobeNewsWire · 3 days ago
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Syndax Pharmaceuticals (NASDAQ:SNDX)Defense World · 3 days ago
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and GrowthGlobeNewsWire · Oct 5, 2026
BioCryst Pharmaceuticals (NASDAQ:BCRX) and BioXcel Therapeutics (NASDAQ:BTAI) Financial ContrastDefense World · Oct 2, 2026
Biopharma Stock With Layers of Technical Support in PlaceSchaeffers Research · Sep 21, 2026BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.15 | $0.30 | Beat |
| May 6, 2026 | $0.06 | -$2.98 | Miss |
| Feb 26, 2026 | $0.07 | $1.12 | Beat |
| Nov 3, 2025 | $0.07 | $0.06 | Miss |
| Aug 4, 2025 | $0.03 | $0.02 | Miss |
| May 5, 2025 | -$0.07 | $0.00 | Beat |